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Abstract We have previously shown that platelet-activating
factor (PAF)-dependent transacetylase (TA) contains three
catalytic activities, namely PAF: lysophospholipid TA (TAL),
PAF: sphingosine TA (TAS) and PAF acetylhydrolase. It serves
as a modifier of PAF actions by producing different lipid signal
molecules. The TAL activity is involved in the biosynthesis of
acyl analogs of PAF (acyl-PAF, 1-acyl-2-acetyl-sn-glycero-3-
phosphocholine, acylacetyl-GPC) in agonist-stimulated endothe-
lial cells. In the present investigation, we have studied the
mechanism(s) by which the TA activity is regulated in ATP-
treated endothelial cells. We have demonstrated that ATP, and
thiol-modifying agents with ATP, specifically regulate only the
TAL part of the TA activities. ß 2000 Federation of European
Biochemical Societies. Published by Elsevier Science B.V. All
rights reserved.
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1. Introduction
We have identi¢ed two enzyme activities, namely, platelet-
activating factor (PAF): lysophospholipid transacetylase (TA)
(TAL) and PAF: sphingosine TA (TAS), that can modify PAF
functions by converting PAF to analogs of PAF and N-acetyl-
sphingosine (C2-ceramide), respectively [1,2]. Analogs of PAF,
such as acyl analogs of PAF, are the predominant compo-
nents in activated endothelial cells, mast cells and basophils
[3], and in two B-lymphoblastoid cell lines [4]. The generation
of acyl analogs of PAF is also detected in stimulated primary
cultures of human keratinocytes [5]. They act as the compet-
itor of PAF and have their own unique biological property [6].
C2-ceramide, used widely by many investigators as a perme-
able analog of long-chain acyl ceramide, is involved in apo-
ptosis, cell cycle arrest and senescence [7^9]. We have shown
that C2-ceramide is a naturally occurring compound and that
TAS is responsible for its biosynthesis [2]. The cellular con-
centration of C2-ceramide (micromolar) is in the similar con-
centration range that elicits its biological e¡ects [2].
To establish the structural and functional relationships be-
tween TAL and TAS, we have puri¢ed TAL to apparent
homogeneity from rat kidney membrane and cytosol with a
molecular mass of 40 kDa [10]. The amino acid sequences of
peptides isolated from tryptic digest of the puri¢ed TAL from
both membranes and cytosol share total homologues with
those of deduced amino acid sequences obtained from the
cDNA of rat intracellular cytosolic PAF acetylhydrolase
(AH) II [11,12]. In addition, puri¢ed TAL from rat kidney
membranes cross-reacts with a mouse monoclonal antibody
against human PAF AH II [13]. The most intriguing of the
¢ndings is that the puri¢ed TA contains all three enzymatic
activities, namely, TAL, TAS and AH [10].
We have elucidated that TAL is activated through direct/
indirect phosphorylation by several agonists, including ATP,
in endothelial cells [6]. The induction of this enzyme is partly
responsible for the increased incorporation of [3H]acetate into
acyl analogs of PAF. The purpose of the present investigation
is to use this cellular system to determine whether the TAL
portion of the TA activities is speci¢cally enhanced and the
mechanism(s) responsible for regulating this speci¢city. We
examined the e¡ects of ATP on these three separate activities
of TA and their intracellular movements. In addition, the
e¡ects of thiol-modifying agents on the biosynthesis of acyl
analogs of PAF were investigated.
2. Materials and methods
2.1. Materials
1-O-Hexadecyl-2-acetyl-GPC, ATP, BSO (L-buthionine-(SR)-sul-
foximine), N-acetylcysteine (NAC), diamide (DA) and N-acetylsphin-
gosine (C2-ceramide) were obtained from Sigma. 1-O-Alkyl-2-acetyl-
GPC was from Avanti. Alkenyllyso-sn-glycero-3-phosphoethanol-
amine was a product from Serdary Research Lab. 1-O-Hexadecyl-2-
[3H]acetyl-GPC (13.5 Ci/mmol) and 1-O-[1P,2P-3H]hexadecyl-2-acetyl-
GPC (60 Ci/mmol) were purchased from NEN Life Science Products.
Sphingosine was bought from Matreya, Inc. All culture reagents were
from Life Technologies, Inc.
2.2. Cell culture and isolation of membrane and cytosolic fractions
Calf pulmonary artery endothelial cells (CPAE, CCL-209) between
passages 19 and 25 were used for experiments as described [6]. Ho-
mogenates were prepared from con£uent cells treated with or without
1 mM ATP for 5 min [6]. Postnuclear fraction (500Ug supernatant)
was centrifuged at 100 000Ug for 60 min to isolate the pellet as the
membrane fraction and the supernatant as the cytosolic fraction. The
protein of the isolated fractions was determined by the method of
Lowry et al. [14].
2.3. Determination of the rate of transfer of [3H]acetyl group from
alkyl[3H]acetyl-GPC into acyl[3H]acetyl-GPC
Monolayers of cells twice washed with 10 ml of Hanks’ balanced
salt solution^10 mM HEPES (pH 7.2) were incubated with 2.0 or 2.5
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WCi of hexadecyl[3H]acetyl-GPC in the presence or absence of 1 mM
ATP for 10 min. Isolation and puri¢cation of radyl[3H]acetyl-GPC
from the lipid extracts of the control and treated cells and determi-
nation of the distribution of the subclasses (alkyl-, acyl- and alkenyl-)
of radyl[3H]acetyl-GPC were as previously described [6].
2.4. Determination of the rate of incorporation of [3H]acetate into
radyl[3H]acetyl-GPC
Monolayers of CPAE cells in complete culture media were incu-
bated with or without 250 WM BSO for 24 h, and then washed mono-
layers of cells were incubated with 25 WCi of [3H]acetate in the pres-
ence or absence of 1 mM ATP for 10 min as described [6]. The CPAE
cells were treated similarly with NAC (10 mM) and DA (0.5 mM)
except the incubation time was 1 h in serum-free media. The amounts
of [3H]acetate incorporated into radyl[3H]acetyl-GPC and subclasses
of radyl[3H]acetyl-GPC were measured in these cell samples with dif-
ferent treatments according to the methods outlined [6].
2.5. Determination of degradation of PAF to lyso-PAF
Treatment of CPAE cells with ATP and DA was identical to the
conditions described in Section 2.4 except that [1P,2P-3H]hexadecyl-
acetyl-GPC (2.5 WCi) instead of [3H]acetate was incubated with the
cells for 10 min. Various cell samples were then extracted for lipids
[15]. The amounts of [1P,2P-3H]PAF converted to [1P,2P-3H]lyso-PAF
in the lipids were determined by thin-layer chromatography and liquid
scintillation counting [6].
2.6. TA assays and PAF AH assay
TAL and TAS activities were determined as established before
[1,2,6,10]. PAF AH was determined according to our previously de-
scribed method [16].
3. Results
3.1. E¡ects of ATP on the TAL, TAS or AH activity
We have reported [6] that the speci¢c activity of PAF:
acyllyso-GPC TA (TAL) in endothelial cells is rapidly stimu-
lated 4-fold by ATP through direct/indirect phosphorylation.
The activation of this enzyme may contribute to the increased
incorporation of [3H]acetate into acyl analogs of PAF in these
cells. On the other hand, the ATP had a minimal e¡ect on the
PAF AH activity. In the present study, we show that the TAS
activity of the TA is also not in£uenced by ATP treatment of
the endothelial cells. The speci¢c activity of TAS is 0.20 þ 0.01
nmol/min/mg protein (means þ S.E.M., n = 3) in the untreated
cells and 0.22 þ 0.02 nmol/min/mg protein (means þ S.E.M.,
n = 3) in ATP-treated cells.
3.2. E¡ects of ATP on the transfer of acetyl group from
hexadecyl[3H]acetyl-GPC to acyl[3H]acetyl-GPC
The activity of lyso-PAF: acetyl-CoA acetyltransferase,
which can be responsible for the biosynthesis of both PAF
and acyl analogs of PAF, is likewise stimulated by ATP [6].
Therefore, it is possible that the increased incorporation of
[3H]acetate into acyl analogs by ATP may be due to the acti-
vation of lyso-PAF: acetyl-CoA acetyltransferase alone. In
order to rule out this possibility, we determined the e¡ect of
ATP on the rate of transfer of the [3H]acetyl group from
hexadecyl[3H]acetyl-GPC into acyl[3H]acetyl-GPC as an index
for the TAL activity in intact cells. When hexadecyl[3H]acetyl-
GPC was incubated with endothelial cells in the presence or
absence of ATP as described in Section 2, we found that the
same amounts of hexadecyl[3H]acetyl-GPC were incorporated
into untreated and ATP-treated cells (49 þ 2.6% (means
þ S.E.M., n = 3) vs. 48 þ 4.9% (means þ S.E.M., n = 3), respec-
tively). However, the amounts of [3H]acetyl group transferring
from hexadecyl[3H]acetyl-GPC into acyl[3H]acetyl-GPC in-
creased from 4.1 þ 0.7% (means þ S.E.M., n = 3) in the control
cells to 9.0 þ 0.6% (means þ S.E.M., n = 3) in ATP-treated cells
(P6 0.001). These results indicate that the induction of TAL
activity is indeed re£ected in the enhanced biosynthesis of acyl
analogs of PAF in ATP-treated cells and ATP does not a¡ect
the AH activity.
3.3. E¡ects of thiol-modifying agents on the incorporation of
[3H]acetate into radyl[3H]acetyl-GPC and its subclasses
Several recent reports [17^19] have indicated that the thiol
(i.e. glutathione) level regulates the cytokine-mediated apopto-
sis and the degradation of sphingomyelin to ceramide. More-
over, AH activity of the TA protects oxidant stress-induced
cell death [20], and TAS activity of TA may participate in
Fig. 1. E¡ect of BSO, DA and NAC on ATP-stimulated incorporation of [3H]acetate into radyl[3H]acetyl-GPC. Monolayers of CPAE cells
were incubated with 250 WM BSO in complete media for 24 h, with DA (0.5 mM) or NAC (10 mM) in serum-free media for 1 h, and then fur-
ther incubated with [3H]acetate in the presence or absence of 1 mM ATP for 10 min before termination of the reactions and isolation of the
products as described under Section 2. Data are presented as means þ S.E.M. (n = 3). The P values between cells treated with ATP and cells
treated with ATP and thiol-modifying agents (BSO/DA) were 6 0.05. There was no di¡erence in P values between NAC- and NAC+ATP-
treated cells.
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apoptosis. Therefore, we studied the e¡ects of thiol level-
modi¢ed agents on the incorporation of [3H]acetate into
PAF analogs to evaluate the in£uences of these agents on
the TAL activity. Data in Fig. 1 depict the incorporation of
[3H]acetate into radyl[3H]acetyl-GPC of BSO/ATP-, DA/
ATP- and NAC/ATP-treated cells and their respective control
cells. Both BSO and DA are thiol oxidizing reagents, while
NAC is a thiol antioxidant [17,18,21]. When CPAE cells were
treated with BSO and DA, the incorporation of [3H]acetate
into radyl[3H]acetyl-GPC increased 185% and 125%, respec-
tively, in BSO/ATP- and DA/ATP-treated cells over that of
the ATP-treated cells alone (Fig. 1). On the contrary, NAC
blocked the stimulated incorporation of [3H]acetate into ra-
dyl[3H]acetyl-GPC by ATP completely (Fig. 1).
The e¡ect of thiol-modulating agents on the amounts of
[3H]acetate incorporated into the subclasses of radyl-
[3H]acetyl-GPC in control and ATP-treated cells was further
analyzed. We found that BSO and DA increase the incorpo-
ration of [3H]acetate into acyl[3H]acetyl-GPC in ATP-treated
cells, while NAC blunts the ATP e¡ect somewhat (Fig. 2).
These data demonstrate that the cellular thiol level in ATP-
activated cells in£uences TAL activity.
When the e¡ect of DA on AH activity in ATP-treated en-
dothelial cells was investigated by using the conversion of
[3H]PAF to [3H]lyso-PAF as a parameter, we found that
both DA and ATP had minimal e¡ects on the rates of cellular
uptake of [3H]PAF (data not shown). Furthermore, the rate
of conversion of [3H]PAF to [3H]lyso-PAF was not in£uenced
by the ATP treatment or the addition of DA to ATP-treated
cells (Fig. 3). Therefore, the activation of TA by ATP specif-
ically increases the TAL portion of the TA activity and the
thiol agents only modify the induced TA activity.
3.4. Translocation of TAL activity from cytosol to membrane in
ATP-treated CPAE cells
In order to determine whether direct/indirect phosphoryla-
tion of TAL induced by ATP [6] may cause the translocation
of TAL to the membrane, we measured the e¡ect of ATP on
the subcellular distribution of TAL. As indicated in Fig. 4,
ATP induced the translocation of TAL from cytosol to mem-
brane by approximately 180% (from 14.9% in the membrane
fractions in untreated cells to 26.7% in the same fraction of
ATP-treated cells). Concomitantly, translocation of TAL to
the membrane by ATP also caused an increase in speci¢c
activity of TAL in membranes by 200% (89 pmol/min/mg pro-
tein in the membrane fraction of untreated cells vs. 177 pmol/
min/mg protein in the membrane fraction of ATP-treated
cells). The speci¢c activity of TAL in the cytosol remained
the same in both control and treated cells (data not shown).
These data indicated that induced translocation of TAL by
ATP with concomitant increase in its speci¢c activity is a
speci¢c event, because the cellular locations of the AH activ-
ities and proteins are not a¡ected by ATP treatment of the
cells (Fig. 4).
4. Discussion
In this study, we showed that ATP induces only the TAL,
but not TAS or AH activity. This in vitro observation was
further validated by the experiments in intact cells. We illus-
trated that ATP increases the incorporation of [3H]acetate
into radyl[3H]acetyl-GPC (Fig. 1). This increase was mostly
re£ected as an increase in the [3H]acetate incorporation into
Fig. 4. E¡ect of ATP on the subcellular distributions of TAL, AH
and protein in CPAE cells. Cytosols and membrane fraction (MF)
were isolated from postnuclear fractions of the CPAE cells that
were treated with or without ATP (1 mM) for 5 min and used to
determine TAL, AH and protein as described under Section 2. Data
are representative of four separate experiments that showed similar
results.
Fig. 2. E¡ect of BSO, DA and NAC on ATP-stimulated incorpora-
tion of [3H]acetate into acyl[3H]acetyl-GPC. Samples from each
group in Fig. 1 were analyzed for the incorporation of [3H]acetate
into acyl[3H]acetyl-GPC as described in Section 2.
Fig. 3. The e¡ect of DA on the conversion of [1P,2P-3H]PAF to
[1P,2P-3H]lyso-PAF in ATP-treated endothelial cells. Monolayers of
CPAE cells were treated with DA (0.5 mM) in serum-free media for
1 h before further incubation with [1P,2P-3H]PAF and/or 1 mM
ATP for 10 min. The methods of analyzing [3H]PAF and [3H]lyso-
PAF were described under Section 2. Data are expressed as
means þ S.E.M. (n = 3). Statistical analyses indicated that the di¡er-
ences between control vs. DA-treated group, control vs. ATP-
treated group, ATP-treated vs. DA+ATP-treated group were insig-
ni¢cant (P values s 0.1 and higher).
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acyl[3H]acetyl-GPC (Fig. 2). Consistent with these data,
we further demonstrated that the conversion of hexade-
cyl[3H]acetyl-GPC into acyl[3H]acetyl-GPC was also increased
by the treatment of endothelial cells with ATP (see Section
3.2). Again, the hydrolysis of [1P,2P-3H]hexadecylacetyl-GPC
to [1P,2P-3H]hexadecyllyso-GPC (a marker for AH, Fig. 3) in
intact cells was not a¡ected by ATP. These results indicate
that the activation of TA by ATP causes the speci¢c stimula-
tion of TAL activity in the TA.
Our data indicated that modulation of thiol levels in the
cells also a¡ects TA activities (Fig. 1). The induction of TAL
activity in ATP-treated endothelial cells was further increased
by thiol oxidants (BSO and DA), and inhibited by antioxidant
(NAC) (Fig. 1). On the other hand, a thiol agent such as DA
had no e¡ect on the AH activity of the TA (Fig. 3). These
results likewise imply that posttranslational modi¢cation of
the TA by ATP, such as phosphorylation of the enzyme,
regulates the speci¢city of TA activities in intact cells.
Along with the TAL activity, but not AH and TAS activ-
ities, being stimulated by ATP, there was a corresponding
translocation of TAL from cytosol to membrane (Fig. 4). It
is feasible, but as yet needs to be proven, that phosphoryla-
tion of TAL by ATP treatment of the cells [6] induces the
translocation of TA to the membranes with a concurrent in-
crease in enzymatic activity. On the other hand, it is also
feasible that modi¢cation of TA, and subcellular translocation
of TA each or in combination, regulates the catalytic activities
of TA.
Matsuzawa et al. [20] also reported that intracellular AH II
translocated from cytosol to membranes when MDBK cells
were treated with oxidants. Conversely, AH II was translo-
cated from membranes to cytosol when cells were treated with
antioxidant [20]. They suggested that intracellular AH II
translocates between cytosol and membrane in response to
the redox state of the cells and protects the cell against oxi-
dative stress most probably by hydrolyzing oxidized phospho-
lipids. However, they did not determine the e¡ect of subcel-
lular translocation of AH II on its enzyme activity.
Our work suggests that TA regulated by various agents,
including purinergic agonists and oxidant stress, can be re-
sponsible for some of the diverse biological functions eluci-
dated by PAF. These e¡ects generated in the cells through TA
do not need the participation of intracellular PAF receptor(s).
Currently, we are studying the mechanism(s) by which a vari-
ety of agents modify the di¡erent activities of TA.
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